The value of the Cell Line Development market is projected to grow to with an estimated CAGR of 5 % by
The global cell line development market is estimated to reach USD 10,838.5 million by the end of 2028. The increased in demand for monoclonal antibodies is considered as one of the major driving factors which promotes the growth of the market. In addition, rise in vaccine production across the world is the another factor which assist in driving the growth of the market. Furthermore, technological advancement accelerating the scaleup the cell lines further synergies the growth of the market. However, the high cost of the process is the major restraining cause that affects the growth of the market. Ongoing risk of pandemic and communicable diseases followed by demand from low income countries will become the huge opportunities during the forecasted year.
Primary cell lines are not fast dividing and have finite lifespan i.e. Hayflick limit. In addition, when these cells reach confluence (i.e. monolayer), the cell stops dividing or proliferating. This phenomenon is termed as Contact inhibition of proliferation (CIP). When the normal cells are transformed into cancer cells, these cells lose the property of contact inhibition. The cells keep on dividing and forms multi-layer mass of cells. The cells do not respond to the growth inhibitory signals and apoptosis. For cancer development, both genetic and epigenetic factors are needed. There are different approaches to the transformation process. Three of them are listed are use of oncovirus infection, embryonic stem cells or induced pluripotent stem cells, telomerase lengthening activation (TLA)
Oncoviruses are those viruses whose infection cause the development of cancer. Embryonic stem cells are pluripotent and have a long lifespan until they differentiate. These cells are often used to generate infinite cell lines. In addition, the adult cells/ differentiated cells such as skin cells can also be reverted to Embryonic stem cells by induced pluripotent stem cells method. Telomerase restoration allows several types of somatic cells to stabilize telomeres. It would bypass senescence and make the cells immortal by defining telomere maintenance, telomerase activity, and cellular immortalization. This method may or may not cause neoplastic transformation.
The Covid 19 pandemic first entered in 2019 and later it disrupted society at the global level. The doctor is giving the first preference to COVID patients and emergency patients followed by the others. There is an urgent need for vaccines in order to save the maximum number of patients suffering from COVID 19. Whole world gone under strong research and development in order to clear all the clinical trials associated with the development of vaccines. Refrigerator or freezer plays a very important role in the transportation of vaccines. The COVID 19 pandemic made a positive impact on the medical refrigerator business.
The major players operating in the global cell line development market include but are not limited to American Type Culture Collection (ATCC), Lonza Group AG , Thermo Fisher Scientific, Inc., GE Healthcare, Sigma-Aldrich Corporation, Selexis SA , European Collection of Cell Cultures (ECACC), Corning, Inc., WuXi AppTec, Inc., Sartorious AG and Others.
Cell Line Development Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 10,838.5 Million|
|Growth Rate||CAGR of 12.01% during 2021-2028|
|Segment Covered||Product Type, Application, Type, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, Middle East & Africa|
|Key Players Profiled||Culture Collection (ATCC), Lonza Group AG , Thermo Fisher Scientific, Inc., GE Healthcare, Sigma-Aldrich Corporation, Selexis SA , European Collection of Cell Cultures (ECACC), Corning, Inc., WuXi AppTec, Inc., Sartorious AG and among others.|
Key Segments of the Global Cell line development market
Product Type Overview, 2018-2028 (USD Million)
- Biosafety Cabinets
- Cell Counters and Viability Systems
- Storage Equipment
- Cell Culture Refrigerators and Freezers
- Cell Culture Cryogenic Storage
- Automated Systems
- Filtration Systems
- Media and Reagents
- Fetal Bovine Serum
- Adult Bovine Serum
- Other Animal Serum
- Minimum Essential Media
- Reduced Serum Media
- Serum-free Media
- Supplements and Growth Factors
- Buffers and Chemicals
- Cell Dissociation Reagents
- Cryopreservative Reagents
Type Overview, 2018-2028 (USD Million)
Application Overview, 2018-2028 (USD Million)
- Recombinant Protein Therapeutics
- Tissue Engineering & Regenerative Medicines
- Toxicity Testing
- Drug Discovery
Regional Overview, 2018-2028 (USD Million)
- North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
Frequently Asked Questions (FAQ) :
The cell line development market is expected to grow with a CAGR of 12.3% in the coming years. The increasing demand for monoclonal antibodies, rising vaccine production, and use of innovative technologies propel the growth of the market. COVID 19 stimulates the growth of healthcare centers. The COVID 19 pandemic has shown huge positive impact on cell line development market.
In the future, the make will face a high degree of competition from its rivals due to entry of the various new market players. Some of the opportunities for the market are low income countries like India and Africa lacking access to basic healthcare and increasing risk of pandemic and communicable diseases. However, in spite of innovative technologies in the market, developing stable and authentic cell lines remains a major challenge of this market.
The international market player will continuously focus on offering technically advanced and low cost innovative products for their customers. Some of the leading players that played a major role in the development of the market are American Type Culture Collection (ATCC), Lonza Group AG, Thermo Fisher Scientific, Inc., GE Healthcare , Sigma-Aldrich Corporation, including others.
Based on type, the cell line development market is classified into six types equipment, media and reagent. The equipment segment is further classified into Biosafety Cabinets, Cell Counters and Viability Systems, incubators, Centrifuges, Bioreactors, Storage Equipment, Automated Systems, Microscopes, Filtration Systems and Others. The equipment segment hold the largest market share in the year 2020. The equipment segment accounts for more than 70% of the total market share. Technological advancement in the area of biotechnology is the major factor responsible for the growth and development. Furthermore, advanced healthcare needs is the second most important factor which leads the growth of the market.
Based on type of cell, the cell line development are classified into primary cell lines, continuous cell lines, hybridomas and recombinant cell lines. The continuous cell lines dominates the global cell line development market. The same segment will grow at the highest CAGR% during the forecasted year. Global demand for the monoclonal antibodies is increasing continuously is the another factor which assist in propelling the growth of the market followed vaccine production across the world.
Based on Application, the cell line development market is classified into bio production, tissue engineering & regenerative medicines, toxicity testing, research and drug discovery. Tissue engineering & regenerative medicines accounts for more 15% of the global market share in the year 2020. The tissue engineering is a branch of biomedical engineering used for organs or tissue to restore the normal biological function. Technological advancement lead to increase the usage of cell line development in tissue engineering.
Based on the source type, the cell line development market is classified into mammalian type and non-mammalian type. Mammalian type segment hold the largest market share in the year 2020. The same segment will grow at the fastest CAGR% during the forecasted year. It is estimated that the mammalian segment accounts for more than 80% of the global market shares in the global cell line development market. The most widely used mammalian cell system is Chinese hamster ovary (CHO) cell culture, which results in antibodies that are glycosylated at asparagine-297 (N297).
The cell line development market is growing rapidly. Despite its demand, each region shows a rapid rise in the research and development. North America seems to dominate the global cell line development market. The United States is the major driver for the North America region. Europe always is known for the prosperous regions in the world, and soon the region will also known for its geriatric population. The rising vaccine production not only in Europe but some countries of Asia Pacific like China, India is considered as one of the major driving factors for the growth of the market. Asia Pacific countries like India and China which together hold 34% of the total world population are also looking for a huge investment in- cell line development market. The recent economic boom of this region coupled with rising per-capita healthcare expenditures is also a major factor. Latin American market is dominated by Brazil and Argentina. Brazil holds more than 62% of the total market shares in 2020.